The proportion of families with at least one initially healthy household contact in whom influenza developed was smaller in the zanamivir group than in the placebo group (4 percent vs. 19 percent ...

Among the 414 family contacts who received zanamivir, influenza developed in 7 (1.7 percent), as compared with 40 of the 423 contacts who received placebo (9.5 percent).

The number of patients and clinicians who enrolled in the study was 26 170; the number who responded to the questionnaire was 14 328 (13 432 patients and 896 clinicians), including 1356 ...

Objective: A patient survey was conducted by questionnaire to evaluate patient acceptance and perceptions of efficacy with zanamivir (Glaxo Wellcome), the first in a new class of neuraminidase ...

Naoki Kawai, Hideyuki Ikematsu, Nobuo Hirotsu, Tetsunari Maeda, Takashi Kawashima, Osame Tanaka, Satoshi Yamauchi, Kenichi Kawamura, Shinro Matsuura, Mika Nishimura, Norio Iwaki, Seizaburo Kashiwagi, ...

(HealthDay)—Oseltamivir and zanamivir reduce the time to symptomatic improvement in influenza by about half a day, but evidence to support claims of reduced admissions to hospital or ...

Inhaled zanamivir was noninferior to oral oseltamivir in preventing severe influenza-related outcomes in a study of more than 865,000 outpatients in Taiwan, ...

In May 2014, following the publication of the Cochrane collaboration reviews for oseltamivir and zanamivir in the prophylaxis and treatment of influenza; the Institute re-issued a consultation on our ...